| $385M | ||
| $350M | ||
| $215M | ||
| $88M | ||
| $82M | ||
| $62M |
Buys | $0 | 0 | – |
Sells | $0 | 0 | – |
Pyxis Oncology, Inc., a preclinical stage biopharmaceutical company, engages in the development of therapies to treat cancers. Its immune-oncology product candidates include PYX-106, an investigational fully human immunoglobulin G1 isotype siglec-15 targeting antibody for the treatment of thyroid cancer, head and neck squamous cell carcinoma, non-small cell lung cancer (NSCLC), and other solid tumors; and PYX-102, an investigational immune-therapeutic for treatment of solid tumors. The company's antibody drug conjugate (ADC) product candidates comprise of PYX-201, an investigational novel ADC to treat NSCLC, breast cancer, and other solid tumors; PYX-202, an investigational novel ADC for treatment of SCLC, soft tissue sarcoma, and other solid tumors; and PYX-203, an investigational ADC for the treatment of acute myeloid leukemia and myeloid dysplastic syndrome. The company was incorporated in 2018 and is headquartered in Cambridge, Massachusetts.
Over the last 12 months, insiders at Pyxis Oncology, Inc. have bought $0 and sold $0 worth of Pyxis Oncology, Inc. stock.
On average, over the past 5 years, insiders at Pyxis Oncology, Inc. have bought $5.91M and sold $2.7M worth of stock each year.
There was no buying activity among insiders over the last 12 months.
The last purchase of 88,850 shares for transaction amount of $174,364 was made by Connealy Pamela Ann (CFO & COO) on 2024‑11‑26.
| 2024-11-26 | Connealy Pamela Ann | CFO & COO | 88,850 0.1619% | $1.96 | $174,364 | -25.42% | ||
| 2023-09-28 | Connealy Pamela Ann | CFO and COO | 8,000 0.0167% | $1.87 | $14,960 | +76.96% | ||
| 2023-09-27 | Connealy Pamela Ann | CFO and COO | 6,426 0.0147% | $1.85 | $11,868 | +95.92% | ||
| 2023-09-27 | Wadhane Jitendra | Chief Accounting Officer | 2,500 0.0058% | $1.87 | $4,675 | +95.92% | ||
| 2023-09-25 | Connealy Pamela Ann | CFO and COO | 12,000 0.0257% | $1.67 | $20,044 | +101.97% | ||
| 2023-09-25 | Wadhane Jitendra | Chief Accounting Officer | 5,000 0.0113% | $1.77 | $8,850 | +101.97% | ||
| 2023-09-22 | Connealy Pamela Ann | CFO and COO | 5,000 0.0124% | $1.74 | $8,695 | +123.75% | ||
| 2023-09-22 | Wadhane Jitendra | Chief Accounting Officer | 2,500 0.0062% | $1.74 | $4,349 | +123.75% | ||
| 2023-09-18 | Sale | Sullivan Lara | President and CEO | 8,541 0.02% | $2.10 | $17,936 | +73.77% | |
| 2023-09-14 | Sale | Sullivan Lara | President and CEO | 100 0.0002% | $2.25 | $225 | +60.55% | |
| 2023-09-13 | Sale | Sullivan Lara | President and CEO | 3,000 0.007% | $2.27 | $6,816 | +56.25% | |
| 2023-09-12 | Sale | Sullivan Lara | President and CEO | 4,917 0.0114% | $2.25 | $11,071 | +57.21% | |
| 2023-09-11 | Sale | Sullivan Lara | President and CEO | 20,000 0.045% | $2.27 | $45,414 | +51.30% | |
| 2023-03-17 | PFIZER INC | 10 percent owner | 1.81M 5.1245% | $2.76 | $5M | -10.51% | ||
| 2022-04-21 | Sale | Chin Mark | 1.75M 6.1916% | $3.05 | $5.32M | -16.98% | ||
| 2021-12-08 | Cline Darren S | director | 10,000 0.0316% | $9.39 | $93,885 | -71.08% | ||
| 2021-11-18 | Civik Thomas | director | 15,700 0.048% | $12.74 | $200,018 | -78.75% | ||
| 2021-10-13 | Chin Mark | director | 312,500 1.3218% | $16.00 | $5M | -70.72% | ||
| 2021-10-13 | Cormorant Asset Management, LP | 450,000 1.9034% | $16.00 | $7.2M | -70.72% |
| PFIZER INC | 10 percent owner | 5952263 9.5597% | $7.92M | 1 | 0 | <0.0001% |
| Sullivan Lara | President and CEO | 2403882 3.8608% | $3.2M | 0 | 5 | |
| Connealy Pamela Ann | CFO & COO | 1199143 1.9259% | $1.59M | 5 | 0 | +74.64% |
| Cormorant Asset Management, LP | 1118854 1.7969% | $1.49M | 1 | 0 | <0.0001% | |
| Wadhane Jitendra | Chief Accounting Officer | 226937 0.3645% | $301,826.21 | 3 | 0 | +107.21% |
| Civik Thomas | director | 15700 0.0252% | $20,881.00 | 1 | 0 | <0.0001% |
| Cline Darren S | director | 10000 0.0161% | $13,300.00 | 1 | 0 | <0.0001% |
| Chin Mark | 0 0% | $0 | 1 | 1 | <0.0001% |
$5,262,089 | 154 | 5.62% | $96.13M | |
$30,470,407 | 140 | 20.39% | $100.96M | |
$5,354,267 | 110 | -35.34% | $72.58M | |
$9,405,928 | 107 | 12.61% | $94.27M | |
$155,630,608 | 79 | -24.53% | $93.43M | |
$4,898,715 | 46 | 40.75% | $87.35M | |
$77,146,704 | 43 | 13.28% | $96.63M | |
$909,129 | 37 | 42.19% | $81.23M | |
$36,180,184 | 32 | 41.36% | $90.52M | |
$1,602,584 | 20 | 15.26% | $78.63M | |
$33,128,160 | 18 | -13.64% | $79.13M | |
$20,234,041 | 17 | 2.09% | $80.25M | |
$11,267,080 | 15 | -22.36% | $82.41M | |
Pyxis Oncology, Inc. (PYXS) | $17,741,707 | 13 | 30.23% | $82.81M |
$1,073,250 | 10 | 19.46% | $96.3M | |
$110,013 | 5 | 6.58% | $77.26M | |
$112,382,168 | 4 | -48.89% | $88.96M | |
$401,951 | 4 | 57.41% | $71.34M | |
$19,175,155 | 2 | 40.00% | $74.91M |
| Increased Positions | 41 | +50.62% | 8M | +40.05% |
| Decreased Positions | 34 | -41.98% | 4M | -20.68% |
| New Positions | 21 | New | 5M | New |
| Sold Out Positions | 12 | Sold Out | 740,722 | Sold Out |
| Total Postitions | 88 | +8.64% | 23M | +19.36% |
| Laurion Capital Management Lp | $4,170.00 | 5.85% | 3.63M | 0 | 0% | 2025-09-30 |
| Tang Capital Management Llc | $2,875.00 | 4.03% | 2.5M | 0 | 0% | 2025-09-30 |
| Vanguard Group Inc | $2,489.00 | 3.49% | 2.16M | +14,566 | +0.68% | 2025-09-30 |
| Perceptive Advisors Llc | $1,355.00 | 1.9% | 1.18M | +1M | New | 2025-09-30 |
| Palo Alto Investors Lp | $1,193.00 | 1.67% | 1.04M | 0 | 0% | 2025-09-30 |
| Millennium Management Llc | $938.00 | 1.32% | 815,331 | -3M | -76.97% | 2025-09-30 |
| Stempoint Capital Lp | $793.00 | 1.11% | 689,538 | +689,538 | New | 2025-09-30 |
| Blackrock, Inc. | $786.00 | 1.1% | 683,702 | -243,103 | -26.23% | 2025-09-30 |
| Bank Of America Corp /De/ | $708.00 | 0.99% | 615,922 | +593,853 | +2,690.89% | 2025-09-30 |
| Renaissance Technologies Llc | $663.00 | 0.93% | 576,336 | +158,514 | +37.94% | 2025-09-30 |